Precision medicine for pediatric cardiomyopathy: lessons from pediatric oncology
Briganti, Francesca, Deshpande, Shriprasad R., Rosenthal, David N., Scheinker, David
Springer Nature ·
2026-11-01
· DOI 10.1038/s44161-026-00900-9
Аннотация
The greatest barrier to precision medicine in pediatric cardiomyopathy may no longer be biology but classification. Reclassifying cardiomyopathy into mechanism-specific rare diseases could provide an operational framework for targeted therapies and precision trials.
Briganti, Francesca, Deshpande, Shriprasad R., Rosenthal, David N. et al. Precision medicine for pediatric cardiomyopathy: lessons from pediatric oncology. // Nature Cardiovascular Research. – 2026. – DOI: 10.1038/s44161-026-00900-9. – URL: https://www.nature.com/articles/s44161-026-00900-9
Briganti, Francesca, Deshpande, Shriprasad R, Rosenthal, David N, Scheinker, & David (2026). Precision medicine for pediatric cardiomyopathy: lessons from pediatric oncology. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-026-00900-9
Briganti, et al. “Precision medicine for pediatric cardiomyopathy: lessons from pediatric oncology.” Nature Cardiovascular Research, 2026. doi:10.1038/s44161-026-00900-9.
@article{Briganti2026,
title = {Precision medicine for pediatric cardiomyopathy: lessons from pediatric oncology},
author = {Briganti and Francesca and Deshpande and R., Shriprasad and Rosenthal and N., David and Scheinker and David},
journal = {Nature Cardiovascular Research},
year = {2026},
doi = {10.1038/s44161-026-00900-9},
url = {https://www.nature.com/articles/s44161-026-00900-9}
}